Persistence with anti|tumour necrosis factor therapies in patients ...

Persistence with anti-tumour necrosis factor therapies in patients ...

Abstract. Introduction: Anti-TNF therapies represent a breakthrough in the treatment of severe psoriatic arthritis. However, little is known about long-term ...

Persistence with anti-tumour necrosis factor therapies in patients ...

The present observational study, reflecting clinical practice in the UK, has shown that persistence with anti-TNF agents in PsA is good, with an estimated 1- ...

Persistence with Anti-Tumor Necrosis Factor Therapies in Patients ...

This analysis demonstrated that the overall treatment persistence with first- and second-course anti-TNF therapies was similar for patients ...

SAT0571 Persistence with Anti-Tumor Necrosis Factor Therapies in ...

The mean duration of (standard deviation) follow-up was 2.5 years ±3.8. During the period of follow-up, 65 patients received a second anti-TNF therapy ( ...

Comparative persistence of anti-tumor necrosis factor therapy in ...

One-year persistence was less likely in Brazil for both anti-TNF and cDMARDs (Brazil: 62.1 and 30.7%, Quebec: 66.9 and 67.0%). The 2-year persistence rates were ...

Long-term persistence of TNF-inhibitor treatment in patients with ...

Results At 5 years, 46.7% of patients were still on their initial TNFi treatment. Better 5 -year persistence was associated with male gender, use of etanercept ...

Prevalence and predictors of tumour necrosis factor inhibitor ...

Persistence with TNFi therapy in second-line users ... A total of 32 patients had switched to using a second TNFi (59% to adalimumab, 41% to ...

Comparative persistence of anti-tumor necrosis factor therapy in ...

The 2-year persistence rates were lower for both anti-TNF and cDMARD, but remained higher in Quebec (Brazil: 47.9 and 18.1%, Quebec: 51.5 and 53.5%). In ...

Persistence of tumor necrosis factor inhibitor or conventional ...

Among the evaluable patients with existing TNFi monotherapy (n = 251), csDMARD monotherapy (n = 225), and combination therapy (n = 214), 93, 87, ...

Persistence with Early-Line Abatacept versus Tumor Necrosis Factor ...

Conclusions: In a real-world setting, RA patients treated with abatacept were more likely to stay on treatment longer and had a lower risk of ...

Persistence Among Patients with Crohn Disease Previously Treated ...

Persistence after a switch to a different biologic class or after cycling within the anti-TNF class was assessed in patients with nonresponse to an anti-TNF ...

Persistence With Anti-Tumour Necrosis Factor Therapies in Patients ...

Anti-TNF therapies represent a breakthrough in the treatment of severe psoriatic arthritis. However, little is known about long-term drug ...

Table 3 Patient withdrawal due to adverse events: first course of anti ...

Anti-TNF therapies represent a breakthrough in the treatment of severe psoriatic arthritis. However, little is known about long-term drug persistence with ...

Tumor Necrosis Factor Inhibitor Persistence in Patients with ...

A total of 32 patients were switched to a second TNFi (59% to adalimumab and 41% to etanercept) and persistence at 12 months was 56%. Although ...

Treatment Persistence and Clinical Outcomes of Tumor Necrosis ...

Among patients with at least 1 year of follow-up after the initial change in therapy [TNFi cyclers, N = 279 (84.0%); new MOA switchers, N = 241 ...

Impact of persistence with tumour necrosis factor inhibitors on ...

Persistence with SC TNF inhibitors within first 12 months following treatment initiation was low in both treatment-naïve and treatment- ...

S966 Persistence Among Patients with Ulcerative Colitis...

In ulcerative colitis (UC), anti-TNF agents often are first-line biologic therapy. Switching to a different class of biologics (ustekinumab, vedolizumab) or ...

Factors associated with cause-specific discontinuation of long-term ...

AS patients on their first anti-TNF treatment for at least two years demonstrated a favorable long-term treatment retention rate, with a 24.0% ...

Persistence with anti-tumor necrosis factor therapies in patients with ...

CONCLUSION: In this population, first- and second-course persistence was similar among anti-TNF therapies. First-course discontinuation due to ...

Data from the Sicilian Network for Inflammatory Bowel Diseases (SN ...

BACKGROUND AND OBJECTIVE:Older people with inflammatory bowel disease (IBD) appear to have a lower response to anti-tumour necrosis factor (TNF) therapy, ...